<DOC>
	<DOCNO>NCT01283139</DOCNO>
	<brief_summary>To evaluate efficacy safety sifalimumab compare placebo subject moderately severely active Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Sifalimumab Adults With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This Phase 2b , multinational , multicenter , randomize , double-blind , placebo control , parallel group study evaluate efficacy safety three intravenous ( IV ) treatment regimens sifalimumab ( 200 , 600 , 1,200 mg ) adult subject chronic moderately-to-severely active SLE inadequate response standard care ( SOC ) SLE .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Fulfills least 4 American College Rheumatology ( ACR ) criteria systemic lupus erythematosus ( SLE ) include positive antinuclear antibody ( ANA ) elevate dsdeoxyribonucleic acid ( DNA ) Sm antibody screen Disease history SLE great equal ( &gt; = ) 24 week screen Weight ( &gt; ) 40 kilogram ( kg ) Currently receive stable dose oral prednisone and/or antimalarials/immunosuppressives Active moderate severe SLE disease base SLE disease activity score ( SLEDAI ) British Isles Lupus Assessment Group Index ( BILAG ) Physicians Global Assessment No evidence cervical malignancy PAP within 6 month randomization Female subject must willing avoid pregnancy Negative TB test newly positive TB test due latent TB treatment must initiate randomization . Active severe SLEdriven renal disease unstable renal disease prior screen Active severe unstable neuropsychiatric SLE Clinically significant active infection include ongoing chronic infection History human immunodeficiency virus ( HIV ) Confirmed Positive test Hepatitis B positive test hepatitis C History severe herpes infection herpes encephalitis , ophthalmic herpes , disseminate herpes Herpes Zoster within 3 month screen History cancer basal cancer cervical cancer treat apparent success &gt; =1 year prior randomization Receipt biologic agent within 5 halflives prior loss pharmacodynamic and/or clinical effect ( whichever longer ) prior screen Live attenuate vaccine within 4 week prior screen Subjects substance abuse Subjects significant hematologic abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Sifalimumab</keyword>
	<keyword>MEDI-545</keyword>
</DOC>